The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Probes Contracts Between Drugmakers, Pharmacy Benefit Managers

U.S. Probes Contracts Between Drugmakers, Pharmacy Benefit Managers

May 11, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The U.S. Attorney’s Office for the Southern District of New York is investigating contracts between drugmakers and companies that manage prescription benefits, according to regulatory filings.

You Might Also Like
  • Kentucky Launches Probe into Drug Overcharges by Pharmacy Benefit Managers
  • Rheumatologists Air Frustrations with Pharmacy Benefit Managers at Annual Meeting
  • U.S. Drug Benefit Managers Clamp Down on Specialty Pharmacies

Federal prosecutors have approached at least three companies, including Johnson & Johnson, Merck & Co. and Endo International Plc., demanding information about their contracts with pharmacy benefit managers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pharmacy benefit managers, or PBMs, which administer drug benefits for employers and health plans and also run large mail-order pharmacies, have been challenging the rising cost of new medications.

When drugs are knocked off their formularies, patients may have to pay full price for them. PBMs often keep or dump a product depending on whether they can obtain favorable pricing.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

J&J said in a regulatory filing on Tuesday it had received a “civil investigative demand”, seeking information about its contractual relationships with pharmacy benefit managers over some of its products from early 2006 through the present.

Merck said on Monday it had received a demand for information about contracts with, services from and payments made to PBMs in relation to its migraine drug, Maxalt, and erectile dysfunction treatment Levitra, over the same period.

Endo said last week it was cooperating with such an investigation, looking into its PBM contracts for its migraine therapy, Frova.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The companies did not disclosed the name of any PBM in their respective filings. Express Scripts Holding Co is the nation’s largest pharmacy benefit manager, followed by CVS Health.

J&J, Merck and Endo and CVS were not immediately available for comment. Express Scripts and the U.S. attorney’s office for the Southern District of New York declined to comment.

Last November, a U.S. unit of Swiss drugmaker Novartis AG agreed to pay $390 million to settle U.S. charges that it paid specialty pharmacies illegal kickbacks in exchange for inducing patients to refill certain medications.

The sector has come under intense scrutiny, particularly after Canadian drugmaker Valeant Pharmaceuticals International Inc was forced to sever ties with Philidor Rx over the specialty pharmacy’s billing practices.

Filed Under: Drug Updates, Pharma Co. News Tagged With: cost, drug, drug development, Legal, pharmaceutical company, pharmacy

You Might Also Like:
  • Kentucky Launches Probe into Drug Overcharges by Pharmacy Benefit Managers
  • Rheumatologists Air Frustrations with Pharmacy Benefit Managers at Annual Meeting
  • U.S. Drug Benefit Managers Clamp Down on Specialty Pharmacies
  • Novartis to Pay $390 Million in U.S. Settlement over Pharmacy Kickbacks

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)